Conference on Clinical Cancer Research
Past Event
Consensus among stakeholders is needed to find solutions to critical questions regarding the future of clinical cancer research. Throughout this day-long conference, panelists sought to address this challenge, discussing pressing scientific and regulatory challenges and opportunities for progress in innovations in cancer therapy. The first three panels discussed options for clinical data standards, alternative methods for demonstrating the efficacy of promising therapies, and approaches to the joint development of cancer drugs and diagnostic tests. The final panel explored the vision for the future of FDA – looking at how FDA can guide innovation and respond to the challenges of a quickly advancing field.
Featured panelists included Dr. Mark McClellan, Dr. David Kessler, Dr. Ellen Sigal, Dr. Janet Woodcock, and others representing the industry, advocacy, regulatory, and academic and government research communities. NCI Director Dr. John Niederhuber made opening remarks, and FDA Commissioner Dr. Andrew von Eschenbach delivered a luncheon keynote address.
The event was convened by the Engelberg Center for Health Care Reform at Brookings in conjunction with the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and Friends of Cancer Research hosted the Conference on Clinical Cancer Research.
Meeting Materials:
Panel 1 Issue Brief »
Panel 2 Issue Brief »
Panel 3 Issue Brief »
Agenda
Welcome and Introductions
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
John Niederhuber
Director, National Cancer Institute
Panel 1: Data Submission Standards and Evidence Requirements
Richard Schilsky
Chief Medical Officer - American Society of Clinical Oncology
Jeffrey Abrams
National Cancer Institute
Gwen Fyfe
Consultant
Robert Erwin
Marti Nelson Cancer Foundation
Janet Woodcock
Director, Center for Drug Evaluation and Research - US Food and Drug Administration
Panel 2: Improved Insights into Effects of Cancer Therapies
Moderator: Raymond DuBois, MD
M.D. Anderson Cancer Center
Jim Doroshow, MD, FACP
National Cancer Institute
Debasish Roychowdhury, MD
GlaxoSmithKline
Nancy Roach
C3: Colorectal Cancer Coalition
Luncheon Keynote
Andrew von Eschenbach
Commissioner, FDA
Panel 3: Co-Development of Diagnostics & Therapeutics
Moderator: Daniel Hayes, MD
University of Michigan
Raymond Woosley
Critical Path Institute
Richard Simon, DSc
National Cancer Institute
Nancy Roach
C3: Colorectal Cancer Coalition
Panel 4: Vision for the Future of FDA
Moderator: Robert Young, MD
Fox Chase Cancer Center
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
Anna Barker
National Cancer Institute
David Epstein
Novartis
Ellen Sigal, PhD
Friends of Cancer Research
Final Questions & Closing Comments
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
More Information
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.